Because upfront treatment with ICI, most often combined PD-1/CTLA-4 blockade, is standard in patients with advanced melanoma, the question arises as to the optimal therapy for those patients who do not respond to ICI or experience disease progression. Here, PDCD1 is linked to melanoma.